Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer (2015)

Peer-Reviewed Study · Kwon YJ; Petrie K; Leibovitch BA; Zeng L; Mezei M; et al. · August 2015

Kwon YJ et al., 2015-08: In silico screen identifying avermectins (ivermectin, selamectin) as small-molecule mimetics of the SIN3-interaction-domain peptide that block SIN3-PAH2 binding, re-express CDH1 and ESR1 and restore tamoxifen sensitivity in triple-negative breast cancer models.

Both selamectin and ivermectin phenocopied the effects of SID peptide to block SIN3-PAH2 interaction with MAD, induce expression of CDH1 and ESR1, and restore tamoxifen sensitivity in MDA-MB-231 human and MMTV-Myc mouse TNBC cells in vitro.

n/a (HTML full text)

Kwon YJ et al., 2015-08: In silico screen identifying avermectins (ivermectin, selamectin) as small-molecule mimetics of the SIN3-interaction-domain peptide that block SIN3-PAH2 binding, re-express CDH1 and ESR1 and restore tamoxifen sensitivity in triple-negative breast cancer models. Study type: in silico screen + TNBC cell lines (MDA-MB-231, MMTV-Myc mouse cells) and mouse tumour work. N: not stated in the abstract. Country: USA (Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York). Dose: not stated in the abstract. Funder: not stated in the retrieved record. Declared COI: 'The authors disclose no potential conflicts of interest.' Product: the paper names ivermectin as Mectizan (Merck's brand). Comparator: SID peptide, untreated cells, tamoxifen alone. This is the 'Kwon YJ et al. 2015' epigenetic SIN3 lead in the prompt, confirmed.